Kura Oncology Taps Biopharma Veteran Jennifer Fulk as CFO
Event summary
- Jennifer Fulk appointed CFO of Kura Oncology, effective September 8, 2026.
- Fulk brings 20+ years of biopharma finance experience, including roles at Eli Lilly and Soleno Therapeutics.
- Kura Oncology is transitioning to a commercial-stage company with KOMZIFTI®, its FDA-approved menin inhibitor.
- Fulk will oversee capital allocation, investor relations, and financial strategy for Kura’s precision oncology pipeline.
The big picture
Kura Oncology’s appointment of Jennifer Fulk as CFO underscores its shift toward commercialization, following the FDA approval of KOMZIFTI. Fulk’s background in biopharma finance and public company leadership positions Kura to optimize capital allocation and investor relations as it scales its precision oncology portfolio. The move reflects broader industry trends where biotech firms prioritize strategic financial leadership to navigate commercialization and R&D investments.
What we're watching
- Commercial Execution
- How Fulk’s experience will drive KOMZIFTI’s market penetration and revenue growth.
- Pipeline Strategy
- Whether Kura can sustain momentum in advancing ziftomenib and darlifarnib amid competitive pressures.
- Capital Allocation
- The pace at which Kura allocates resources to high-value opportunities while maintaining financial discipline.
Related topics